GLP-1 Generics Could Reshape Local Obesity Market

Original Article by Tanya Pampalone, Mia Malan and Anna-Maria van Niekerk | Bhekisisa Centre for Health Journalism | 24 August 2026

GLP-1 generics could cut obesity drug costs, challenge illegal sales and expand access as more semaglutide products seek approval.

Image | Haberdoedas | Unsplash/aLCcungJbrc

GLP-1 generics could cut obesity drug costs, challenge illegal sales and expand access as more semaglutide products seek approval.

Subscription Required

You must be a subscriber to access all of this content.

Already a subscriber? Log in here

Cancer sugar shield research from UCT reveals how tumours evade immunity and could support new vaccines, biomarkers and precision therapies.

Parmed medical aid reform could make membership voluntary for MPs, judges and other office-bearers, opening access to alternative schemes.

Gap cover is becoming essential as medical aid shortfalls, co-payments and specialist fees increase pressure on members.